Who is sponsoring NCT00607295?

NCT00607295 is sponsored by Seoul National University Hospital.

What condition does NCT00607295 study?

NCT00607295 studies Breast Cancer, Vaginal Atrophy.

What drugs are being tested in NCT00607295?

Interventions: clino-san vaginal lubricant.

What is the status of NCT00607295?

NCT00607295 is currently COMPLETED.

Last reviewed 2010-07-23 · How we verify

Prospective Randomized Study on Efficacy and Safety of Clino-san® in the Management of Vaginal Dryness in Breast Cancer Patients

NCT00607295 Phase 3 COMPLETED

1. Although after treatment for breast cancer such as chemotherapy or hormonal therapy, urogenital atrophy is common, the patients are seldomly treated for several reasons. Management of this problem is important for improving quality of life. 2. "Clino-san" is a kind of vaginal lubricant with pH 5 which is similar pH of premenopausal vaginal discharge. After randomization of patients, they are treated with Clino-san or placebo 3 times/week for 12 weeks. 3. We check the vaginal symptoms, vag dryness severity score, and ultrasonography at baseline, 4, 8, and 12 weeks of treatment.

Details

Lead sponsor	Seoul National University Hospital
Phase	Phase 3
Status	COMPLETED
Enrolment	98
Start date	2007-12
Completion	2009-02

Conditions

Breast Cancer
Vaginal Atrophy

Interventions

clino-san vaginal lubricant

Primary outcomes

vaginal dryness score — for 12 weeks

Countries

South Korea